About
Nocion Therapeutics develops charged small-molecule sodium-channel blockers called nocions that selectively silence activated sensory neurons to treat conditions such as chronic cough, itch, and pain. Their lead program, Taplucainium, is in a global Phase 2b trial for refractory chronic cough.
Explore Nocion Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.